Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR AI

Date Submitted: Feb 20, 2026
Open Peer Review Period: Feb 20, 2026 - Apr 17, 2026
Date Accepted: Sep 30, 2026
(closed for review but you can still tweet)

The final, peer-reviewed published version of this preprint can be found here:

Conversational Multi-Agentic Network-Driven Disease Module Identification and Drug Repurposing Prediction With ChatDRex: Platform Development Study

Süwer S, Bagemihl K, Baier S, Dicunta L, List M, Baumbach J, Maier A, Delgado-Chaves FM

Conversational Multi-Agentic Network-Driven Disease Module Identification and Drug Repurposing Prediction With ChatDRex: Platform Development Study

JMIR AI 2026;5:e93862

DOI: 10.2196/93862

PMID: 42976355

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Conversational No-code, Multi-agentic Disease Module Identification and Drug Repurposing Prediction with ChatDRex

  • Simon Süwer; 
  • Kester Bagemihl; 
  • Sylvie Baier; 
  • Lucia Dicunta; 
  • Markus List; 
  • Jan Baumbach; 
  • Andreas Maier; 
  • Fernando Miguel Delgado-Chaves

ABSTRACT

Repurposing approved drugs offers a time-efficient and cost-effective alternative to traditional drug development. However, in silico prediction of repurposing candidates is challenging and requires the effective collaboration of specialists in various fields, including pharmacology, medicine, biology, and bioinformatics. Fragmented, specialized algorithms and tools often address only narrow aspects of the overall problem. Heterogeneous, unstructured data landscapes require the expertise of specialized users. Hence, these data services do not integrate smoothly across workflows. With ChatDRex, we present a conversation-based, multi-agent system that facilitates the execution of complex bioinformatic analyses aiming for network-based drug repurposing prediction. It builds on the integrated systems medicine knowledge graph (NeDRex KG). ChatDRex provides natural language access to its extensive biomedical knowledge base. It integrates bioinformatics agents for network analysis, literature mining, and drug repurposing. These are complemented by agents that evaluate functional coherence for in silico validation. Its flexible multi-agent design assigns specific tasks to specialized agents, including query routing, data retrieval, algorithm execution, and result visualization. A dedicated reasoning module keeps the user in the loop and allows for hallucination detection. By enabling physicians and researchers without computer science expertise to control complex analyses with natural language, ChatDRex democratizes access to bioinformatics as an important resource for drug repurposing. It enables clinical experts to generate hypotheses and explore drug repurposing opportunities, ultimately accelerating the discovery of novel therapies and advancing personalized medicine and translational research.


 Citation

Please cite as:

Süwer S, Bagemihl K, Baier S, Dicunta L, List M, Baumbach J, Maier A, Delgado-Chaves FM

Conversational Multi-Agentic Network-Driven Disease Module Identification and Drug Repurposing Prediction With ChatDRex: Platform Development Study

JMIR AI 2026;5:e93862

DOI: 10.2196/93862

PMID: 42976355

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.